We have utilized deceased donor livers to maintain low mortality on the wait list, to provide a significantly high transplant rate, and to achieve excellent graft and patient outcomes at 3 months, one year, and 3 years, surpassing the national and expected averages. We have also shown that reLT remains a durable option for patients with recurrent disease including recurrent HCV, that DCD livers continue to be a viable source of donor grafts, and that LT in patients with high BMI produces acceptable outcomes.
|Original language||English (US)|
|Number of pages||9|
|State||Published - 2008|
ASJC Scopus subject areas